Abstract

Aim: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy. Methods: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. χ2 tests were used for comparisons of interest across groups. Results: Respondents were 68% male and 53% African-American, with a mean age of 47 years. Overall, 73% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61% with weekly dosing; 72% every 2 weekly; and 84% monthly. In total, 48% indicated that they were very concerned about the possible side effects and 35% were very concerned about needle use. Conclusion: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy.

Original languageEnglish (US)
Pages (from-to)1807-1813
Number of pages7
JournalNanomedicine
Volume8
Issue number11
DOIs
StatePublished - Jan 1 2013

Fingerprint

human immunodeficiency virus
Needles
Gages
HIV
Injections
Public Opinion
African American
Therapeutics
interest group
African Americans
gauge
therapy
Surveys and Questionnaires

Keywords

  • AIDS
  • HIV
  • antiretroviral therapy
  • intravenous drug abuse
  • nanoformulated antiretroviral therapy
  • nonadherence
  • substance abuse

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)

Cite this

Long-acting parenteral nanoformulated antiretroviral therapy : Interest and attitudes of HIV-infected patients. / Williams, Jennifer; Sayles, Harlan R.; Meza, Jane L; Sayre, Patrick; Sandkovsky, Uriel; Gendelman, Howard Eliot; Flexner, Charles; Swindells, Susan.

In: Nanomedicine, Vol. 8, No. 11, 01.01.2013, p. 1807-1813.

Research output: Contribution to journalArticle

Williams, Jennifer ; Sayles, Harlan R. ; Meza, Jane L ; Sayre, Patrick ; Sandkovsky, Uriel ; Gendelman, Howard Eliot ; Flexner, Charles ; Swindells, Susan. / Long-acting parenteral nanoformulated antiretroviral therapy : Interest and attitudes of HIV-infected patients. In: Nanomedicine. 2013 ; Vol. 8, No. 11. pp. 1807-1813.
@article{a49de30a8cc343309d1645663759d43f,
title = "Long-acting parenteral nanoformulated antiretroviral therapy: Interest and attitudes of HIV-infected patients",
abstract = "Aim: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy. Methods: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. χ2 tests were used for comparisons of interest across groups. Results: Respondents were 68{\%} male and 53{\%} African-American, with a mean age of 47 years. Overall, 73{\%} of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61{\%} with weekly dosing; 72{\%} every 2 weekly; and 84{\%} monthly. In total, 48{\%} indicated that they were very concerned about the possible side effects and 35{\%} were very concerned about needle use. Conclusion: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy.",
keywords = "AIDS, HIV, antiretroviral therapy, intravenous drug abuse, nanoformulated antiretroviral therapy, nonadherence, substance abuse",
author = "Jennifer Williams and Sayles, {Harlan R.} and Meza, {Jane L} and Patrick Sayre and Uriel Sandkovsky and Gendelman, {Howard Eliot} and Charles Flexner and Susan Swindells",
year = "2013",
month = "1",
day = "1",
doi = "10.2217/nnm.12.214",
language = "English (US)",
volume = "8",
pages = "1807--1813",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "11",

}

TY - JOUR

T1 - Long-acting parenteral nanoformulated antiretroviral therapy

T2 - Interest and attitudes of HIV-infected patients

AU - Williams, Jennifer

AU - Sayles, Harlan R.

AU - Meza, Jane L

AU - Sayre, Patrick

AU - Sandkovsky, Uriel

AU - Gendelman, Howard Eliot

AU - Flexner, Charles

AU - Swindells, Susan

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Aim: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy. Methods: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. χ2 tests were used for comparisons of interest across groups. Results: Respondents were 68% male and 53% African-American, with a mean age of 47 years. Overall, 73% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61% with weekly dosing; 72% every 2 weekly; and 84% monthly. In total, 48% indicated that they were very concerned about the possible side effects and 35% were very concerned about needle use. Conclusion: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy.

AB - Aim: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy. Methods: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. χ2 tests were used for comparisons of interest across groups. Results: Respondents were 68% male and 53% African-American, with a mean age of 47 years. Overall, 73% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61% with weekly dosing; 72% every 2 weekly; and 84% monthly. In total, 48% indicated that they were very concerned about the possible side effects and 35% were very concerned about needle use. Conclusion: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy.

KW - AIDS

KW - HIV

KW - antiretroviral therapy

KW - intravenous drug abuse

KW - nanoformulated antiretroviral therapy

KW - nonadherence

KW - substance abuse

UR - http://www.scopus.com/inward/record.url?scp=84887248504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887248504&partnerID=8YFLogxK

U2 - 10.2217/nnm.12.214

DO - 10.2217/nnm.12.214

M3 - Article

VL - 8

SP - 1807

EP - 1813

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 11

ER -